CUANDO EL APRENDIZAJE PASA A SER UNA ACTITUD


/ cursos_formacion/articulos-cientificos-sobre-covid-19-y-diabetes/

Nuestro objetivo es mejorar la esperanza y la calidad de vida de los pacientes con diabetes.

/ Artículos científicos sobre COVID 19 y Diabetes

Compartir en redes :


En las últimas semanas han aparecido en medios internacionales diversos artículos que relacionan la pandemia del COVID 19 con la Diabetes. En este enlace hacemos una recopilación de los artículos más destacados, para su descarga y consulta:

  • Admission Hyperglycemia and Radiological findings of SARS-COv2 in patients with and without Diabetes_Iacobellis Diabetes Res Clin Pract
  • Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19_Zhang P. Circ Res
  • Clinical characteristics and outcomes of patients with severe covid-19 with diabetes_Yan Y. BMJ Open Diabetes Res Care
  • Clinical Characteristics of 28 Patients With Diabetes and Covid-19 in Wuhan, China_Wang F. Endocrine Pract
  • Clinical considerations for patients with diabetes in times of COVID-19 epidemic_Gupt R. Diabetes Metab Syndr
  • Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications_Drucker DJ. Endocr Rev
  • COVID-19 and diabetes-Can DPP4 inhibition play a role_Iacobellis Diabetes Res Clin Pract
  • COVID-19 and Diabetes-Knowledge in Progress_Hussain A. Diabetes Res Clin Pract
  • COVID-19 and DM-What we know, how our patients should be treated now, and what should happen next_Angelidi AM. Metabolism
  • COVID-19 in patients with diabetes-risk factors that increase morbidity_Umpierrez Metabolism
  • Diabetes in COVID-19-Prevalence, pathophysiology, prognosis and practical considerations_Singh AK. Diabetes Metab Syndr
  • Diabetes is a risk factor for the progression and prognosis of COVID-19_Guo W Diabetes Metab Res Rev
  • Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - A systematic review_Huang I. Diabetes Metab Syndr
  • Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China_Metabolism
  • Endocrine and metabolic link to coronavirus infection_Bornstein SR. Nat Rev Endocrinol
  • Estimation of effects of lockdown on HbA1c and diabetes complications_Ghosal S. Diabetes Metab Syndr
  • Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States_Bode
  • Guidelines for the management of diabetes services and patients during the COVID-19 pandemic_Rayman G-Diabet Med
  • Mechanisms of increased morbidity and mortality of SARS-CoV-2 infection in individuals with diabetes_Metab Clin Exp
  • Metformin in COVID-19 A Possible Role Beyond Diabetes_Sharma-Diabetes Res Clin Pract
  • Practical recommendations for the management of diabetes in patients with COVID-19_Bornstein Lancet
  • Prevalence and impact of cardiovascular metabolic diseases on COVID‐19 in China_Li B. Clin Res Cardiol
  • Prevalence and impact of diabetes among people infected with SARS‐CoV‐2_Fadini J Endocrinol Invest
  • Renin–Angiotensin–Aldosterone System I nhibitors in Patients with Covid 19_Vaduganathan NEJM
  • TOP_Diabetes in COVID-19- Prevalence, pathophysiology, prognosis and practical considerations_Diabetes Metab Syndr 2020
  • No deleterious effect of lockdown due to COVID-19 pandemic on glycaemic control, measured by glucose monitoring, in adults with type 1 diabetes. Pilar Isabel Beato-Víbora

DESCARGABLES

  • Admission-Hyperglycemia-and-Radiological-findings-of...
  • Admission-Hyperglycemia-and-Radiological-findings-of...
  • Association-Inpatient-Use-Angiotensin-Converting-Enz...
  • Association-Inpatient-Use-Angiotensin-Converting-Enz...
  • Clinical-characteristics-and-outcomes-of-patients-wi...
  • Clinical-characteristics-and-outcomes-of-patients-wi...
  • Clinical-Characteristics-28-Patients-Diabetes-COVID-...
  • Clinical-Characteristics-28-Patients-Diabetes-COVID-...
  • Clinical-considerations-patients-with-diabetes-times...
  • Clinical-considerations-patients-with-diabetes-times...
  • Coronavirus-Infections-and-Type-2-Diabetes-Shared-Pa...
  • Coronavirus-Infections-and-Type-2-Diabetes-Shared-Pa...
  • COVID-19-and-diabetes-Can-DPP4-inhibition-play-a-rol...
  • COVID-19-and-diabetes-Can-DPP4-inhibition-play-a-rol...
  • COVID-19-and-Diabetes-Knowledge-in-Progress_Hussain-...
  • COVID-19-and-Diabetes-Knowledge-in-Progress_Hussain-...
  • COVID-19-and-DM-What-we-know-how-our-patients-should...
  • COVID-19-and-DM-What-we-know-how-our-patients-should...
  • COVID-19-in-patients-with-diabetes-risk-factors-that...
  • COVID-19-in-patients-with-diabetes-risk-factors-that...
  • Diabetes-in-COVID-19-Prevalence-pathophysiology-prog...
  • Diabetes-in-COVID-19-Prevalence-pathophysiology-prog...
  • Diabetes-is-a-risk-factor-for-the-progression-and-pr...
  • Diabetes-is-a-risk-factor-for-the-progression-and-pr...
  • Diabetes-is-a-risk-factor-for-the-progression-and-pr...
  • Diabetes-is-a-risk-factor-for-the-progression-and-pr...
  • Diabetes-mellitus-is-associated-with-increased-morta...
  • Diabetes-mellitus-is-associated-with-increased-morta...
  • Diabetes-patients-with-COVID-19-need-better-blood-gl...
  • Diabetes-patients-with-COVID-19-need-better-blood-gl...
  • Endocrine-and-metabolic-link-to-coronavirus-infectio...
  • Endocrine-and-metabolic-link-to-coronavirus-infectio...
  • Estimation-of-effects-of-lockdown-on-HbA1c-and-diabe...
  • Estimation-of-effects-of-lockdown-on-HbA1c-and-diabe...
  • Glycemic-Characteristics-and-Clinical-Outcomes-of-CO...
  • Glycemic-Characteristics-and-Clinical-Outcomes-of-CO...
  • Guidelines-for-the-management-of-diabetes-services-a...
  • Guidelines-for-the-management-of-diabetes-services-a...
  • Mechanisms-of-increased-morbidity-and-mortality-of-S...
  • Mechanisms-of-increased-morbidity-and-mortality-of-S...
  • Metformin-in-COVID-19-A-Possible-Role-Beyond-Diabete...
  • Metformin-in-COVID-19-A-Possible-Role-Beyond-Diabete...
  • Practical-recommendations-for-the-management-of-diab...
  • Practical-recommendations-for-the-management-of-diab...
  • Prevalence-and-impact-of-cardiovascular-metabolic-di...
  • Prevalence-and-impact-of-cardiovascular-metabolic-di...
  • Prevalence-and-impact-of-diabetes-among-people-infec...
  • Prevalence-and-impact-of-diabetes-among-people-infec...
  • Renin%E2%80%93Angiotensin%E2%80%93Aldosterone-System...
  • Renin%E2%80%93Angiotensin%E2%80%93Aldosterone-System...
  • TOP_Diabetes-in-COVID-19-Prevalence-pathophysiology-...
  • TOP_Diabetes-in-COVID-19-Prevalence-pathophysiology-...
  • Pilar-beato-dia.2020.0184.pdf
  • Pilar-beato-dia.2020.0184.pdf

VÍDEOS

    No hay vídeos

Artículos científicos sobre COVID 19 y Diabetes

En las últimas semanas han aparecido en medios internacionales diversos artículos que relacionan la pandemia del COVID 19 con la Diabetes. En este enlace hacemos una recopilación de los artículos más destacados, para su descarga y consulta:

  • Admission Hyperglycemia and Radiological findings of SARS-COv2 in patients with and without Diabetes_Iacobellis Diabetes Res Clin Pract
  • Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19_Zhang P. Circ Res
  • Clinical characteristics and outcomes of patients with severe covid-19 with diabetes_Yan Y. BMJ Open Diabetes Res Care
  • Clinical Characteristics of 28 Patients With Diabetes and Covid-19 in Wuhan, China_Wang F. Endocrine Pract
  • Clinical considerations for patients with diabetes in times of COVID-19 epidemic_Gupt R. Diabetes Metab Syndr
  • Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications_Drucker DJ. Endocr Rev
  • COVID-19 and diabetes-Can DPP4 inhibition play a role_Iacobellis Diabetes Res Clin Pract
  • COVID-19 and Diabetes-Knowledge in Progress_Hussain A. Diabetes Res Clin Pract
  • COVID-19 and DM-What we know, how our patients should be treated now, and what should happen next_Angelidi AM. Metabolism
  • COVID-19 in patients with diabetes-risk factors that increase morbidity_Umpierrez Metabolism
  • Diabetes in COVID-19-Prevalence, pathophysiology, prognosis and practical considerations_Singh AK. Diabetes Metab Syndr
  • Diabetes is a risk factor for the progression and prognosis of COVID-19_Guo W Diabetes Metab Res Rev
  • Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – A systematic review_Huang I. Diabetes Metab Syndr
  • Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China_Metabolism
  • Endocrine and metabolic link to coronavirus infection_Bornstein SR. Nat Rev Endocrinol
  • Estimation of effects of lockdown on HbA1c and diabetes complications_Ghosal S. Diabetes Metab Syndr
  • Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States_Bode
  • Guidelines for the management of diabetes services and patients during the COVID-19 pandemic_Rayman G-Diabet Med
  • Mechanisms of increased morbidity and mortality of SARS-CoV-2 infection in individuals with diabetes_Metab Clin Exp
  • Metformin in COVID-19 A Possible Role Beyond Diabetes_Sharma-Diabetes Res Clin Pract
  • Practical recommendations for the management of diabetes in patients with COVID-19_Bornstein Lancet
  • Prevalence and impact of cardiovascular metabolic diseases on COVID‐19 in China_Li B. Clin Res Cardiol
  • Prevalence and impact of diabetes among people infected with SARS‐CoV‐2_Fadini J Endocrinol Invest
  • Renin–Angiotensin–Aldosterone System I nhibitors in Patients with Covid 19_Vaduganathan NEJM
  • TOP_Diabetes in COVID-19- Prevalence, pathophysiology, prognosis and practical considerations_Diabetes Metab Syndr 2020
  • No deleterious effect of lockdown due to COVID-19 pandemic on glycaemic control, measured by glucose monitoring, in adults with type 1 diabetes. Pilar Isabel Beato-Víbora

 

D: C/Eugenio Salazar 23 (28002) Madrid

T: 914 013 342 

Lunes – Jueves 8:00H / 14:00H – 15:00H/17:00H

Viernes 8:00H / 15:00H

Junio – Septiembre. Lunes – Viernes 8:00H/15:00H

www.sediabetes.org

 

POLÍTICA DE PRIVACIDAD



1) LEY 34/2002, DE SERVICIOS DE SOCIEDAD DE LA INFORMACION, ( L.S.S.I )

En cumplimiento de lo dispuesto en el art. 10 de la Ley 34/2002 de 11 de julio de Servicios de la Sociedad de la Información (L.S.S.I.) se pone en conocimiento de los USUARIOS de esta página, la información relativa a la razón social de la SED, y que a continuación se detalla:

Nombre social: SOCIEDAD ESPAÑOLA DE DIABETES (en adelante, la SED).
CIF: G-78052826.
Domicilio: C/ Eugenio Salazar, 23.
28002 Madrid.
E-mail: web@sediabetes.org.


2) LEY 15/1999 DE PROTECCION DE DATOS DE CARACTER PERSONAL

La SED, con arreglo al Reglamento (UE) 2016/679 de Protección de Datos, le informa que los datos de carácter personal recogidos en cualquiera de los apartados del presente dominio web serán tratados de manera confidencial en ficheros cuyo Responsable del Tratamiento es la SED.

La finalidad del tratamiento es la de gestionar de forma adecuada la prestación del servicio que nos ha requerido, así como para posibles comunicaciones comerciales y/o de prestación de servicios a su correo electrónico, teléfono móvil y/o dirección postal.

Le informamos de la posibilidad de ejercitar sus derechos de acceso, rectificación, cancelación y oposición, limitar el tratamiento de sus datos, directamente oponerse al tratamiento o ejercer el derecho a la portabilidad de estos, ante la SED como Responsable del Tratamiento, a través del correo electrónico: meugeniaruiz@sediabetes.org o por correo ordinario a la dirección C/ Eugenio Salazar 23 (28002) Madrid.

Los datos personales proporcionados serán tratados de forma activa mientras que se ostente la condición de usuario de los productos, servicios o de la información ofrecida a través del presente dominio web; es decir, hasta que se revoque el consentimiento prestado en su caso, o el usuario ejerza sus derechos de supresión u oposición.

Igualmente, le informamos de su derecho a presentar una reclamación ante la Autoridad de Control en materia de Protección de Datos de su país, si considera que el tratamiento de datos personales que le conciernen infringe la normativa vigente.